We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Merck ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Merck stock slumps 38% YoY; Q1 earnings could be a pivotal turning point. Analysts see 29% upside despite bearish technicals and weak recent performance. Get prepared for the Fed’s next move ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations ...

comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Merck performed in the just reported quarter in ...

Merck's stock has been mired in bad news, with concerns around Keytruda and Gardasil's underwhelming performance weighing on its valuation. But to its credit, management is making moves that could ...